New technologies and new methods for enhanced biomacromolecule separations

Biomacromolecules, especially proteins and monoclonal antibodies (mAbs), are emerging as promising therapeutic modalities for treating several chronic diseases. As the complexity of these therapeutics continue to increase, new methods are required by biopharmaceutical companies to fully characterize their drug product and ensure that it is impurity free and safe for the patient.

This webinar will focus on new ultra-high performance liquid chromatography (UHPLC) column technologies that allow the researcher to characterize the biotherapeutic by liquid chromatography mass spectrometry (LC–MS). Aspects of reversed-phase chromatography (RPC), size-exclusion chromatography (SEC), and hydrophilic interaction liquid chromatography (HILIC) will be discussed with respect to characterizing biomacromolecules at different levels of analysis (top-down, middle-down, and bottom-up).

What will you learn?

  • How to apply RPC, SEC, and HILIC in biotherapeutic characterization.
  • Learn about new column technologies and their advantages over older (last generation) columns.
  • Method development strategies for better resolution and efficiency of analyte/impurity peaks.

Who may this interest?

  • Research and Development Scientists, Supervisors & Managers.
  • Quality Control Supervisors/Managers.
  • Biopharmaceutical/Pharmaceutical Scientists.
Cory Muraco x90Cory E. Muraco
Senior R&D Scientist
Cory is a Senior R&D Scientist in the liquid separations R&D group at MilliporeSigma, Bellefonte (PA,USA). He completed his graduate studies at Youngstown State University (OH,USA) in 2013, focusing on the analysis and characterization of oxidized proteins. Upon graduation, Cory joined MilliporeSigma in 2013, first joining the chemical standards R&D group, then transferring to the liquid separations R&D group. His current role at MilliporeSigma is to research, develop, and present on new particle technology for improved chromatographic separations of both small and large molecules as well as to develop new methodologies for characterizing biomacromolecules by several modes of chromatography.

Sponsored by

*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.MERCK VIB_M_CELL_VcRpVm_4C